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Abstract
Background: Papulopustular rash is a common class effect of epidermal growth factor receptor inhibitors (EGFRI)
that can affect patients’ health-related quality of life and cause disruptions to treatment. SWOG S1013
(NCT01416688) is a multi-center study designed to validate the Functional Assessment of Cancer Therapy EGFRI 18
(FACT-EGFRI 18) using 7-items from the National Cancer Institute (NCI) Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0 to assess EGFRI-induced skin-related toxicities and their impact on functional status.
Methods: Patients with a diagnosis of colorectal or lung cancer to receive EGFRI therapies for at least 6 weeks were
enrolled. Patient self-assessments using the FACT-EGFRI 18 were completed prior to undergoing CTCAE assessment
by trained clinicians at baseline, weekly × 6, and then monthly × 3. The psychometric properties of the FACT-EGFRI
14 (skin toxicity items only) and 18 (plus 2 nail and 2 hair items) were established based on criterion validity, known
groups validity, internal consistency reliability, and responsiveness to change.
Results: Of the 146 registered patients, 124 were evaluable. High Cronbach’s alpha (> 0.70) for both FACT-EGFRI 14
and FACT-EGFRI 18 scores across assessment times were observed. Although agreement (i.e. criterion validity)
between individual and summary scales of the FACT-EGFRI 18 for assessing skin toxicity was good, agreement with
the clinician-reported CTCAE was only fair. The minimal important difference was determined to be 3 points. The
results also demonstrated responsiveness to symptom change.
(Continued on next page)
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Discussion: Based on the results of this multi-center validation study, the FACT-EGFRI 18 patient-reported outcome
instrument provided data from the patient’s perspective yielding unique information as well as complementing
clinician-rated CTCAE grades, especially for the symptoms of pain, pruritus, and paronychia.
Conclusions: Good to excellent psychometric properties for the FACT-EGFRI 18 were demonstrated, supporting
further use of this patient-reported outcomes measure. Additional validation with a more diverse group of patients
should be conducted.
Keywords: EGFRI, FACT-EGFRI 18, Dermatologic toxicity, Papulopustular rash, Patient-reported outcome measure,
Health-related quality of life, HRQL
Background
A characteristic rash has been documented to be a “class
adverse effect” of agents that target the epidermal growth
factor receptor (EGFR), including the monoclonal anti-
bodies (Mab) cetuximab and panitumumab, and the tyro-
sine kinase small molecule inhibitor (TKI) erlotinib [1].
Approximately 90% and 75% of cancer patients receiving
EGFR inhibitors (EGFRI) Mabs and TKIs, respectively, de-
velop a papulopustular eruption within the first 2–3 weeks
after the start of therapy, and the toxicity is often dose-
dependent [2–4]. The eruption is characterized by inflam-
matory papules and pustules most often seen on the face,
chest, and back but occasionally extending to the extrem-
ities; scratching due to pruritus can cause secondary infec-
tion. These lesions may resemble folliculitis or an
acneiform drug eruption with tenderness and pruritus.
Multiple large phase III trials of EGFRI therapies have
found drug-related papulopustular rash in 75% of patients,
including 8% with grades 3–4 toxicity [5, 6]. The discom-
fort and physical appearance of this common toxicity
affect patients’ instrumental activities of daily living
(IADL) and health-related quality of life (HRQL), and can
cause disruptions to treatment [7–9].
Interest in rash management has increased over time
due to published data suggesting a possible relationship
between the presence of rash and treatment response
and/or patient survival [8, 10–13]. The current manage-
ment approach is either prophylactic with oral antibi-
otics and topical corticosteroids or reactive treatment
with dose modifications or discontinuation of EGFRIs
upon the occurrence of intolerable Grade 2 or Grade
3 or 4 skin toxicity. No standardized treatment
regimen has been identified as the optimal approach
to prevent or treat EGFRI-induced skin toxicity.
Research to advance knowledge and establish consen-
sus to optimally manage EGFRI-induced skin rash
requires universally accepted, reliable, and validated
patient reported outcome (PRO) measures to comple-
ment the National Cancer Institute Common Toxicity
Criteria and Adverse Events (CTCAE) [14–16]. mea-
sures add the impact of skin toxicities and functional
status assessments.
Between 2010 to 2017, three other grading systems
were proposed [17–19]. None of these systems has been
adopted as the standard of care tool by the medical com-
munity. The National Cancer Institute’s PRO-CTCAE
was an important addition to the small set of patient-
reported symptom measures addressing skin toxicity
symptoms, but were not available when S1013 was de-
veloped [20–24]. One concern is these items do not
thoroughly address the full range of skin toxicities on
functional impacts. The patient-reported instrument
used in this trial, the Functional Assessment of Cancer
Therapy EGFRI 18 (FACT-EGFRI 18) as shown in
Table 1 [25], does address these broad symptoms, but
had not been fully validated. Therefore, there remained
a need to validate a PRO measure to capture patients’
experiences with treatment and effects on HRQL, en-
hance clinicians’ ability to accurately assess the severity
and effect of skin toxicity symptoms, and evaluate inter-
ventions to prevent or manage skin toxicities.
Because of the absence of a validated or “gold stand-
ard” PRO measure to assess EGFRI skin toxicity, a
multi-center study was designed to evaluate the psycho-
metric properties of the FACT-EGFRI 18 [25]. The goal
was to obtain a more comprehensive assessment of
EGFRI-induced skin-related toxicities, particularly with
respect to impact on patient functional status, in order
to inform and promote optimal supportive care as well
as continued research for this patient population.
Methods
Study design
Patients
The trial was conducted by the SWOG (formerly the
Southwest Oncology Group) Cancer Research Network,
a National Cancer Institute (NCI)-sponsored National
Clinical Trials Network group and a member of the
NCI’s Community Oncology Research Program. Eligible
patients, screened and recruited by investigators from 11
SWOG sites, had a diagnosis of colorectal or lung cancer
and were planning to receive one of the following EGFRI
treatment regimens for at least 6 weeks: 1) Cetuximab
400 mg/m2 IV loading dose, 250 mg/m2 IV weekly; 2)
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Cetuximab 500 mg/m2 IV every 2 weeks; 3) Panitumu-
mab 6mg/kg IV every 2 weeks; or 4) Erlotinib 100–150
mg PO daily. Concurrent chemotherapy was allowed, ex-
cept for agents known to cause rash that could interfere
with EGFRI-induced skin toxicity assessment. Patients
receiving prior EGFRI therapy must have fully recovered
from any skin toxicities prior to registration. Patients
must not have been planning to receive concomitant
medications or treatments that could cause rash or other
dermatologic reactions (including radiation therapy) and
must not have any serious concomitant skin disorder
(such as eczema) that could interfere with assessment of
EGFRI-induced skin toxicity. Patients had a Zubrod [26]
performance status of 0–2. Patients completed question-
naires in English.
All patients were informed of the investigational na-
ture of this study and were required to sign and give
written informed consent in accordance with institu-
tional and federal guidelines.
Patient-completed measures: FACT-EGFRI 18 questionnaire
The FACT-EGFRI 18 [25] is a PRO measure to assess
dermatologic-related symptom burden and HRQL
among patients receiving EGFRIs. It includes 18 items
evaluating the physical, functional, emotional, and social
impact of symptoms in three anatomical areas: skin with
14 items, which comprises the FACT-EGFRI 14, plus 2
nail items and 2 hair items. In accordance with standard
FACT administration procedures [27], patients rate each
item using a 5-point Likert scale from 0 (Not at all) to 4
(Very much) based on the past 7 days. Based on the Func-
tional Assessment of Chronic Illness Therapy (FACIT)
scoring system, a higher score indicates better HRQL (e.g.
lower severity of symptoms) [25]. Patient assessments
were completed prior to physician assessments at each
visit. The assessment timepoints occurred prior to EGFRI
initiation at baseline (Day 1) and on Days 8, 15, 22, 29, 36,
and 43; and then monthly for 3months on Days 71, 99
and 127. Assessments continued through Day 127 even if
EGFRI treatment was delayed or discontinued.
Patient-completed measures: anchor items
This two-item patient completed measure addresess the
patient’s sense of the degree of change in the severity of
skin symptoms and the degree of change in the impact
of skin symptoms on the patient’s daily life since the last
time questionnaires were completed [28]. These two
items were used to help estimate a mean level of change
Table 1 The Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFRI 18)
Instructions: “Below is a list of statements that other people with your illness have said are important. Please check one box per line to indicate your
response as it applies to the past 7 days.”
Item
No.
Item Response category
Not at all A little bit Somewhat Quite a bit Very much
1 My skin or scalp feels irritated
2 My skin or scalp is dry or “flaky”
3 My skin or scalp itches
4 My skin bleeds easily
5 I am bothered by a change in my skin’s sensitivity to the sun
6 My skin condition interferes with my ability to sleep
7 My skin condition affects my mood
8 My skin condition interferes with my social life
9 I am embarrassed by my skin condition
10 I avoid going out in public because of how my skin looks
11 I feel unattractive because of how my skin looks
12 Changes in my skin condition make daily life
Difficult
13 The skin side effects from treatment have interfered with household tasks
14 My eyes are dry
15 I am bothered by sensitivity around my fingernails or toenails
16 Sensitivity around my fingernails makes it difficult to perform household tasks
17 I am bothered by hair loss
18 I am bothered by increased facial hair
Note: FACT-EGFRI 18 measure and scoring instructions are available at the following website: https://www.facit.org/FACITOrg/Questionnaires
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in symptom severity and impact experienced by patients
in S1013. The severity item response for minimal level
of change was a little bit better or a little bit worse
(representing a one-point change in either direction). Se-
lection of zero reflected the patient’s sense that symptom
severity was about the same. Very much change (very
much better or worse) was represented by selection of +
2 or − 2. Instead of the mean minimum difference, the
overall mean difference is reported. The same definitions
held for the change in the impact of skin symptoms on
daily life. Patients did not complete the anchor items at
the prestudy assessment time but began completing this
form with the second assessment at day 8. The mean
score for each anchor choice through day 43 for severity
and impact was calculated for a single mean score for
change in severity and change in impact. The results re-
ported in this study intend to emphasize the mean over-
all change in skin toxicity symptom severity and skin
toxicity symptom impact and not the mean minimum
difference.
Clinician-completed measures: CTCAE items
Seven National Cancer Institute Common Toxicity Cri-
teria and Adverse Events (CTCAE) items [15] (Rash
acneiform, Pruritus, Dry skin, Pain of skin, Paronychia,
Alopecia, and Hypertrichosis) addressed criterion valid-
ity for the FACT-EGFRI-18 (Online Appendix Table 1).
These seven items are most commonly associated with
skin toxicity assessment. The grading of the CTCAE
ranges from Grades 1 through 5 with unique clinical de-
scriptions of severity for each adverse event defined as:
Grade 1 =Mild, Grade 2 =Moderate, Grade 3 = severe,
Grade 4 = Life-threatening or disabling, and Grade 5 =
Death. Although the NCI CTCAE items do not have
psychometric documentation similar to that provided for
patient-reported measures, they are widely accepted as
physician/clinician measures of adverse events in cancer
clinical trials. To minimize variability in the ratings, only
physician investigators and the nurse/clinical research
associate at each site who had previously undergone for-
mal training in the CTCAE assessments by SWOG rated
the subjects’ EGFRI-induced skin toxicities.
Clinician-completed measure: performance status items
The Zubrod Scale is the performance status (PS) meas-
ure developed by CG Zubrod for use in cancer clinical
trials [26]. It is the measure used in the Eastern Co-
operative Oncology Group (ECOG) - American College
of Radiology Imaging Network (ACRIN) trials [29]. This
PS measure is a 5-point scale from normal status to un-
able to get out of bed. In S1013, the Zubrod provided a
“history” of PS over the course of the study.
Statistical considerations
The overall goal of this study was to evaluate the psy-
chometric properties of the FACT-EGFRI 18 [25] based
on criterion validity, known groups validity, internal
consistency reliability, and responsiveness to change. To
be considered evaluable for endpoint analyses, patients
must have met all eligibility criteria, completed the base-
line FACT-EGFRI 18 prior to the start of EGFRI treat-
ment, and had valid anchor assessments (Days 1, 8, 15,
or 22) and valid follow-up assessments (Days 29, 36, or
43). A valid assessment is one where the FACT-EGFRI
18 is completed prior to the physician’s evaluation of
skin toxicity. The analysis focused on the psychometric
properties of the FACT-EGFRI 18 [25] through the Day
43 assessment, corresponding to the minimum required
treatment time for eligibility.
Criterion validity
Because there is no validated or “gold standard” PRO
measure available in this setting, criterion validity was
defined as agreement between the FACT-EGFRI 18 [25]
and the CTCAE [15] scoring system. Agreement was
measured using an unweighted Kappa statistic, with
moderate or better agreement defined as Kappa [30] co-
efficients of ≥0.41. Agreement was assessed between the
seven treatment toxicity categories most commonly as-
sociated with EGFRI toxicity and the total and individual
scores from the FACT-EGFRI 18 items. To enable com-
parison between the EGFRI score and the CTCAE grade
using a Kappa statistic [30], total scores for the EGFRI
categories were generated on a scale from 0 to 100.
These scores were then categorized into the number of
respective CTCAE levels using ranks, with cell sizes de-
fined by the patients’ corresponding CTCAE score distri-
butions. Constructing marginal distributions for EGFRI
total scores in this fashion avoids arbitrary categorization
(since it relies on the observed distribution of CTCAE
scores) and also allows for the contingency of perfect
concordance (a desirable property, which is highly un-
likely). Due to the fact that patients could enter this study
with none to any level of skin toxicity and that approxi-
mately 80% of patients receiving the EGFRI agents develop
skin toxicity, we expected to observe a broad range of
such toxicities including none. Only the sixteen items that
explicitly corresponded to CTCAE items were used for
the criterion validity analyses. A table showing items from
both measures is included in the online appendix.
Known groups validity
Known groups validity [31–33] was assessed by examin-
ing differences in mean EGFRI subscores (eg. rash,
pruritus, pain) between patients who reported a PS of 0
(indicating normal activity without symptoms) and
patients who reported feeling any symptoms (PS > 0).
Wong et al. Journal of Patient-Reported Outcomes            (2020) 4:54 Page 4 of 12
ANOVA was used to compare FACT-EGFRI 18 scores
between groups, with differences of 1/3 to 1/2 of a
standard deviation considered of interest [31]. The a
priori hypothesis was that mean scores of the FACT-
EGFRI 18 skin adverse events measure would be signifi-
cantly higher (better) for lower (better) performance
status (based on reported symptom level).
Internal consistency reliability
Internal consistency reliability was evaluated using Cron-
bach’s alpha [34]. Coefficients of > 0.70 are considered
sufficient evidence of reliability [35]. Reliability was
assessed for two scores: the FACT-EGFRI 14 score for
the 14 skin toxicities and the full FACT-EGFRI 18 scale
that included two nail and two hair toxicity items in
addition to the 14 skin toxicities.
Responsiveness to change
Longitudinal regression using linear mixed models (wth
patient treated as a random effect) was used to measure
change in FACT-EGFRI 18 scores over time, with 1/3 to
1/2 of a standard deviation reflecting a clinically signifi-
cant change [31].
Minimal important difference (MID)
The MID for the FACT-EGFRI 18 scores was estimated
by comparing unweighted mean changes in the FACT-
EGFRI 18 score to the patient’s direct assessment of
change between adjacent levels of two anchor items,
severity and impact [28].
Criterion validity, known groups validity and reliability
were described at each timepoint and overall. Secondary
objectives included the assessment of minimally import-
ant change and the association of the FACT-EGFRI 18
scores with treatment profiles.
Power and sample size
The primary objective was to establish the validity of
the new measure through the collection of psycho-
metric properties. The accrual goal was N = 140 eli-
gible patients, among whom 80% (N = 112) were
expected to be evaluable for psychometric endpoints.
For a Kappa [36] of 0.7 and 5 levels and a sample
size of 112 evaluable patients, there is 95% confidence
that the true agreement was at least 0.60 (“good”
agreement), assuming equal levels of agreement and
disagreement for each of the category levels. Given
similar parameters, for a Kappa of 0.4, there is 95%
confidence that the true agreement was at least 0.28
(“fair” agreement).
Results
Research staff at 11 institutions enrolled 146 patients
between November 15, 2011 and October 1, 2016. Two
patients were ineligible: one patient had baseline
performance status greater than 2 and the other did not
have colorectal or lung cancer. Twenty additional pa-
tients were not evaluable (Fig. 1), leaving 124 patients
evaluable for the analysis of psychometric endpoints.
Evaluable patients were 47% (n = 58) male, 16% (n = 20)
non-white and 10% (n = 12) Hispanic, with a median age
of 65 years (range 32–88 years). Thirty one patients
(25%) had performance status of 0 and 75% (n = 93) had
performance status > 0. Fifty-four percent (n = 67) of
evaluable patients were treated with erlotinib, 15% (n =
18) with each of the 2 different dose regimens of cetuxi-
mab, and 17% (n = 21) with panitumumab. Papulopustu-
lar rash developed in 112 (90%) of the evaluable patients.
Maximum per-patient rash severity ratings based on
CTCAE grading were predominantly reported at grade 1
(47%, n = 58) and grade 2 (43%, n = 53), while 10%
(n = 12) reported grade 3; the median onset of the rash
occurred at 2 weeks. Descriptive statistics for the item
and scale scores of the FACT-EGFRI 18 are shown in
Table 2.
Criterion validity
Kappa statistics ranged from − 0.02 to 0.53, varying by
assessment time and skin symptom (Fig. 2). Overall, 26
of the 46 (57%) individual assessment-specific Kappa
statistics were > 0.20, indicating fair agreement between
Fig. 1 Subject Enrollments
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FACT-EGFRI 18 scores and CTCAE scores. Moderate
agreement (≥0.41) for selected timepoints was found for
pain of skin, paronychia, and pruritus. Mean toxicity-
specific Kappa scores exceeded 0.2 for pain of skin,
paronychia, and pruritus only.
Known groups validity
Results of the ANOVA analysis are summarized in Fig. 3.
Since higher FACT-EGFRI 18 subscores indicate better
HRQL, positive standardized values (effect sizes) 0.33 or
higher (MID) were considered of interest. Overall, 32 of
the 56 (57%) individual assessment-specific results
were > 0.33. Mean subscale scores were at least 0.33 for
dry skin, pain of skin, pruritus, and rash acneiform, as
well as for the total FACT-EGFRI 18 score. The full
FACT-EGFRI 18 item scale was used to assess known
groups validity, responsiveness to expected change, and
reliability.
Internal consistency reliability
Cronbach’s alpha statistics are summarized in Fig. 4 by
score and by time point. Reliability estimates were uni-
formly high (> 0.70) for both the FACT-EGFRI 14 and
FACT-EGFRI 18, indicating strong internal consistency
reliability, with every assessment time showing a Cron-
bach’s alpha > 0.70 for each scale.
Responsiveness to change
Figure 5 shows the linear mixed model fitted regression
line results for responsiveness to change. The FACT-
EGFRI 18 total score decreased significantly over time,
consistent with a decrease in HRQL over time. Subscale
scores decreased significantly (p < 0.001) over time for
dry skin, rash acneiform, paronychia, pain of skin, and
pruritus, but not for hypertrichosis (p = 0.42) or alopecia
(p = 0.12).
Minimal important difference (MID)
The mean difference between levels was 3.18 points for
change in severity of skin symptoms, and 3.37 points for
change in impact of skin symptoms (Table 3). Therefore,
a reasonable estimate of the MID in the FACT-EGFRI
18 scores is 3 points. This estimate can be used to indi-
cate the MID in future studies that include the FACT-
EGFRI 18 measure [28].
Association with treatment profiles
Patients who experienced a disruption in EGFRI treat-
ment had lower FACT-EGFRI 18 scores than patients
who did not have a disruption in EGFRI treatment by
the end of the baseline period at assessment Day 22
(57.8 vs.62.2) and the end of the follow-up period at Day
43 (57.2 vs. 63.9).
Table 2 Descriptive Statistics for Total FACT-EGFRI 18 Scale and Subscale Scores*
Mean
(SD)
Day 1 Day 8 Day 15 Day 22 Day 29 Day 36 Day 43 Day 71 Day 99 Day 127
Alopecia 92.4 93.7 93.5 93.6 91.5 90.1 88.3 82.8 79.9 75.0
(18.4) (16.5) (16.5) (17.5) (17.9) (18.0) (21.7) (26.6) (28.5) (30.6)
Dry skin 94.4 90.1 82.1 83.6 86.3 88.3 86.6 85.0 84.5 85.6
(8.7) (13.9) (21.7) (19.3) (16.9) (11.5) (12.6) (16.1) (13.4) (17.4)
Hypertrichosis 96.7 96.1 94.3 95.4 97.4 97.3 95.8 87.8 91.7 86.4
(11.1) (13.8) (17.4) (11.9) (8.6) (8.9) (12.4) (23.6) (22.4) (24.3)
Pain of skin 95.5 86.6 76.1 79.9 82.4 86.9 82.7 83.0 85.4 84.3
(11.4) (18.4) (23.7) (22.7) (20.0) (12.2) (16.9) (18.5) (16.6) (18.5)
Paronychia 96.2 95.2 92.5 87.7 86.8 88.0 82.4 77.2 80.2 75.8
(9.9) (10.3) (14.2) (20.6) (20.3) (16.4) (22.6) (25.3) (26.3) (24.6)
Pruritus 92.8 83.0 74 76.5 78.8 84.9 79.1 80.6 79.2 81.4
(15.1) (22.4) (24.2) (23.4) (21.4) (12.8) (18.3) (18.6) (19.4) (20.5)
Rash 94.9 89.5 80.7 82.8 85.5 88.5 85.2 84.4 84.3 84.7
(8.2) (13.9) (20.7) (18.9) (15.8) (9.7) (13.1) (16.6) (14.5) (16.9)
Total FACT- EGFRI 18 67.9 64.9 60.1 60.8 62.1 63.8 61.5 60.1 60.0 59.6
(5.3) (8.1) (11.8) (10.8) (9.0) (6.0) (8.6) (11.0) (9.9) (11.6)
*Higher FACT-EGFRI scores reflect better health-related quality of life
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Discussion
When evaluating treatment regimens such as EGFRI
that cause considerable skin toxicity that can nega-
tively impact HRQL, it is important to have a vali-
dated instrument to assess the patient perspective.
Our study showed uniformly high Cronbach’s alpha
(> 0.70) for both FACT-EGFRI 14 (skin symptoms
only) and FACT-EGFRI 18 across assessment times,
indicating strong evidence of internal consistency
among the items that make up these two composite
scores. The results also demonstrated responsiveness
to symptom change, and were correlated with treat-
ment profiles. The known groups validity results were
of interest for dry skin, pain of skin, pruritus, rash,
and the total FACT-EGFRI 18 score. Although agree-
ment (i.e. criterion validity) between individual and
summary scales of the FACT-EGFRI 18 and the
current clinician measure for assessing EGFRI skin
toxicity (physician-rated CTCAE items) was generally
only fair, this may reflect the limitations of the
Fig. 2 Criterion Validity For Each Symptom Based on Kappa Statistics Overall (Mean) and by Assessment Day. Criterion validity for the seven
treatment toxicity categories most commonly associated with EGFRI toxicity. Criterion validity is based on agreement between the FACT-EGFRI 18
and the CTCAE scoring systems, and was assessed both overall and by assessment day. Moderate or better agreement is defined as Kappa
coefficients of ≥0.41
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physician-reported CTCAE measure itself. The MID
for the FACT-EGFR 18 was determined to be 3
points. The 2 items that reached the moderate agree-
ment (≥0.41) for the criterion validity analysis were
pain and pruritus, which are non-measurable and
non-observable symptoms. Therefore, the inclusion of
these 2 important skin-related symptoms in a PRO
measure will be informative.
As previously noted, there are no currently available
standardized PRO measures to quantify EGFRI-
induced dermatologic adverse events and impact on
functional status, from the patient’s perspective. Fur-
thermore, the subjective nature of some of these
EGFRI-induced papulopustular rash symptoms (i.e.
pain of skin and itching) make it more appropriate
and accurate to be assessed using the PRO approach.
Dermatology-specific PROs such as the Skindex-29
[37] and the Dermatology Life Quality Index [38] are
available and widely used, but these tools are not spe-
cifically designed to assess EGFRI-associated toxicity,
such as hair change and paronychia. Therefore our
results provide important data to support using the
Fig. 3 Standardized Values for Known Groups Validity. Standardized values for known groups validity. Known groups validity was assessed by
examining differences in mean EGFRI subscores between patients who reported no symptoms (performance status = 0, n = 31) and any
symptoms (performance status > 0, n = 93). ANOVA was used to compare FACT-EGFRI 18 scores between groups, with differences of 1/3 to 1/2 of
a standard deviation considered of interest
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FACT-EGFRI 18 in EGFRI-treated patients to assess
the impact of this specific class of treatment on
HRQL.
This validation study included patients from across
multiple oncology practice sites throughout the United
States treated with a number of different EGFRI-
containing treatment regimens. The included population
was consistent with published experience with these
agents, including incidence and time to development of
the papulopustular rash [2–4]. However it included fewer
than 20% non-white patients and was limited to English
speaking patients, which somewhat limits generalizability.
Fig. 4 Cronbach’s alpha. Cronbach’s alpha is a measure of internal consistency reliability. Reliability was assessed for the FACT-EGFRI 14 14-item
score for the 14 skin toxicities and the full FACT-EGFRI 18 scale of 18 items. Coefficients of > 0.70 are considered sufficient evidence of reliability
Fig. 5 Responsiveness to change between Days 1 and 43
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Overall these data are applicable to most community care
settings and will be important for future clincial trials that
include assessment with the FACT-EGFRI 18.
The FACT-EGFRI 18 provides data from the patient’s
perspective yielding unique information as well as com-
plementing clinician-rated CTCAE grades, especially for
the symptoms of pain, pruritus, and paronychia. With
the introduction of the NCI PRO-CTCAE since the initi-
ation of this trial, additional research should be consid-
ered to optimize the utility of NCI PRO-CTCAE items
in combination with the FACT-EGFRI 18 to best evalu-
ate the EGFRI-induced papulopustular rash.
In conclusion, the psychometric results for the FACT-
EGFRI 18 obtained in S1013 are supportive of use of this
measure in English-speaking patients with cancer under-
going treatment with EGFRI-containing treatment
regimens.
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FACT EGFRI Total Score
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time
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Mean N Mean N Mean N Mean N Mean N
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Day 29 5.76 20 3.00 23 0.21 55 −2.03 21 −2.5 2
Day 36 4.01 16 2.49 28 −0.31 48 0.53 22 −8 1
Day 43 2.20 17 0.64 19 0.04 54 −4.52 21 −7.25 4
Mean 4.17 1.32 0.13 −3.84 −8.53 3.18
Change in IMPACT of skin symptoms on daily life
Day 8 −1.33 3 0.05 84 −9.17 23 −20.5 6
Day 15 4.5 2 −0.4 10 −1.8 66 −8.73 36 −17.13 8
Day 22 3.36 14 8.44 9 −0.75 79 −4.91 17 4 2
Day 29 7.43 14 2.86 21 0.44 70 −2.57 14 −5 2
Day 36 4.22 16 2.19 18 0.42 70 −1.2 11
Day 43 1.91 18 1.23 13 −0.7 71 −5.1 10 −7.33 3
mean 4.28 2.17 −0.39 −5.28 −9.19 3.37
aUnweighted mean difference calculated as the average of the difference between adjacent levels of patient-reported change categories. For instance, for
severity, the difference is calculated as: mean of [4.17–1.32,1.32–0.13, 0.13-(−3.84), −3.84-(−8.53)]
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